Atossa Therapeutics, Inc.
(NASDAQ : ATOS)

( )
ATOS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
TMOThermo Fisher Scientific, Inc. 2.11%488.001.0%$769.29m
DHRDanaher Corp. 0.78%239.010.7%$656.80m
MDTMedtronic Plc 0.55%124.570.6%$617.90m
ABTAbbott Laboratories 0.69%122.280.8%$605.46m
ALGNAlign Technology, Inc. 0.00%594.936.3%$358.42m
ISRGIntuitive Surgical, Inc. 0.00%785.832.3%$347.03m
SYKStryker Corp. -0.02%252.251.3%$298.93m
NVCRNovoCure Ltd. 0.00%186.006.8%$279.45m
DXCMDexCom, Inc. 0.00%391.107.8%$277.48m
BDXBecton, Dickinson & Co. 0.12%250.111.0%$275.09m
BSXBoston Scientific Corp. -0.03%39.661.0%$244.85m
IDXXIDEXX Laboratories, Inc. 0.16%515.003.7%$224.27m
BAXBaxter International, Inc. 0.07%84.701.8%$220.94m
EWEdwards Lifesciences Corp. -0.04%86.220.4%$220.84m
AAgilent Technologies, Inc. -0.08%131.871.6%$187.81m

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.